CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

Life Science Review Europe.

Life Sciences Review | Wednesday, December 08, 2021
Tweet

Next-generation sequencing significantly predicts likelihood for recurrence in patients treated with tisagenlecleucel. 41 of 42 patients relapsed or advanced to HCT or other treatments after treatment with Kymriah, according to scientists at Utah's Huntsman Cancer Institute.


FREMONT, CA: A recent research found that detecting minimal residual illness using next-generation sequencing was significantly predictive of recurrence in adolescents and young adults with acute lymphoblastic leukemia treated with tisagenlecleucel (Kymriah). Every timepoint from 3 to 12 months following therapy had the detectable disease, with 41 of 42 patients relapsing or advancing to HCT or other treatments, according to Michael Pulsipher, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake City.


A threshold of >0 cells observed is the best biomarker reported so far to predict the likelihood for recurrence following CAR T-cell treatment with tisagenlecleucel, scientists noted in Blood Cancer Discovery. First-year B-cell aplasia also defines patients with potential long-term response. HCT or other cell or immune therapy should be tried for those who lose B-cell aplasia or have NGS-MRD measurements >0 on marrow examination .


  


Multiparametric flow cytometry (MFC) has shown that second-generation CAR T-cell treatments result in MRD-negative remissions in 80-97% of patients. There are no reliable signs to predict recurrence in these individuals, which is one of the obstacles in treating them.


Sara Ghorashian, BM BCh, PhD, and Jack Bartram, BM BCh, of Great Ormond Street Hospital for Children in London,  said that  these results clearly show that NGS-MRD may predict relapse after tisagenlecleucel infusion, accompanying the study. Pulsipher and colleagues compared MFC-MRD with NGS-MRD in 1,771 MFC samples from 143 paediatric and young adult patients involved in the ENSIGN and ELIANA studies.


NGS-MRD was able to detect individuals at risk of recurrence far in advance of relapse in all patients, the scientists observed. The median time to relapse among patients with MRD was 52 days from the first MFC, 70 days from NGS-MRD over the threshold of 106, and 168 days from NGS-MRD below the 106 cutoffs. A combination of B-cell aplasia and bone marrow NGS-MRD measurements was shown to be relevant, since patients who lose B-cell aplasia early perform poorly.


Weekly Brief

loading
Towards a New World Order
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/life-science-review-europe-nwid-661.html